Articles by Nichole Tucker
Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML.
CLL treatment is evolving. Dr. Ryan Jacobs shares why decisions now weigh indefinite therapy vs. time-defined options.
During The HemOnc Pulse Live! Nick Short, MD gave a presentation on unanswered questions in ALL.
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
Linperlisib will be investigated in a global registration study versus physician’s choice of standard treatment for R/R ...
Pallawi Torka, MD, discusses current guidelines and evidence-based strategies for managing DLBCL in older adults.
United States District Judge Sean D. Jordan entered the final judgment to vacate a new FDA regulation regarding lab tests.
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
According to John O. Mascarenhas, MD, the phase 3 MANIFEST study heralds a new era of combination therapy for myelofibrosis.
Readmission rates were higher among patients with AML with high incomes compared with patients with low incomes.
BCMA–directed CAR Ts were a vital advancement to RRMM treatment. Now, oncologists wonder which agent works best.
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.
Results from DALY II USA were presented during the oral abstract session on myeloma and lymphoma at the Tandem TCT Meetings.
Based on promising results from the phase II TELLOMAK study, the FDA grants a breakthrough therapy designation for lacutamab.
Findings from a subgroup analysis of ZUMA-7 support early referral to axi-cel therapy.
Real-world data suggest that treatment with either axi-cel or liso-cel provides potential to sustain disease-free survival.
Based on LINKER-MM1, FDA approval for linvoseltamab is under consideration.
The first study on the efficacy and safety of an IDH1 inhibitor and hypomethylating agent in advanced AML shows success.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.